Aptatek BioSciences, Inc. Closes Funding Tranche Based on Successful Clinical Evaluation of Its PheCheckTM Aptamer-Based In-Home Monitoring Platform
18 Junio 2024 - 11:46AM
Business Wire
Aptatek BioSciences, Inc., a developer of in-home health
monitoring solutions for patients with chronic disease, announced
the completion of a funding round led by Canterbury Scientific,
LDT, and the National PKU Alliance (NPKUA).
The funding, based on the successful initial clinical evaluation
of Aptatek’s first product, will be used to complete clinical
studies of its groundbreaking in-home monitoring platform for
phenylketonuria (PKU). This chronic, rare inherited disorder causes
the dangerous build-up of the amino acid phenylalanine in the body.
Like diabetes, it must be carefully monitored for management
through optimization of diet and medication.
“The continued support of Canterbury Scientific and the NPKUA is
critical for the successful development of our first DNA
aptamer-based application in chronic disease,” said Aptatek CEO Dr.
Michael Boyce-Jacino. “We are delighted to have their endorsement
of our technology and the benefit of their counsel as we continue
to grow.”
Clive Seymour, CEO of Canterbury Scientific, a leading global
OEM supplier of IVD controls, stated, “the Aptatek team is at the
leading edge of chronic disease management. The work they have done
so far has great promise for those dealing with this rare disorder.
We are excited to continue our investment and give them the
guidance they need to be successful.”
“A home-based monitoring system for blood phenylalanine levels
is a critical unmet need for PKU management. We are thrilled to
continue supporting Aptatek’s promising PheCheck platform, which
aims to address this important gap,” said Catherine Warren,
Executive Director of the National PKU Alliance.
A spinout from Columbia University, Aptatek BioSciences, Inc. is
a point-of-care technology company with a unique, aptamer-based
assay chemistry developing products for in-home health
monitoring.
Currently, diagnosis and monitoring of inborn diseases are
performed only in centralized laboratories, which is costly, slow,
and inaccessible to millions of people globally. One such disease
is Phenylketonuria (PKU). Once diagnosed, PKU patients must closely
monitor their phenylalanine levels for their entire lifetimes or
face severe health challenges. PKU patients have no choice but to
visit a hospital or mail blood samples to a central lab.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240618134186/en/
Michael Boyce-Jacino, CEO, Aptatek BioSciences, Inc.
info@aptatek.com, (609) 559-0326